Last reviewed · How we verify
NCT03506529: HYPHYCA
Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
trial testing questionnary in Anal Cancer in 644 participants. Completed in 15 November 2018.
15 November 2018
Quick facts
| Lead sponsor | Centre Francois Baclesse |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 644 |
| Start date | 17 September 2018 |
| Primary completion | 15 November 2018 |
| Estimated completion | 15 November 2018 |
| Sites | 2 locations across France |
Drugs / interventions tested
- questionnary
Conditions studied
- Anal Cancer — all drugs for Anal Cancer →
Sponsor
Centre Francois Baclesse — full company profile →
Who can join
18 and older, any sex, with Anal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Questionnaire to be completed by patients coming for PET to identify the predictive factors of physiological hypermetabolism of the anal canal
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological <sup>18</sup>F-FDG anal uptake.
Aide N, Tainturier LE, Nganoa C, Houdu B, et al · · 2020 · cited 1× · PMID 32193623 · DOI 10.1186/s13550-020-0615-5
Verify or expand the search:
- PubMed search for NCT03506529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of questionnary
Trials testing the same drug.
- NCT06485297 — Effect Tunnel in Oral Medicine · completed
- NCT05701020 — Evaluation of Prevalence of Sexuality Alteration in Women With an Abnormal Pap Test · NA · completed
- NCT03040505 — Future Mental Projections in Schizophrenia · terminated
Other recruiting trials for Anal Cancer
Currently open trials in the same condition.
- NCT07192055 — Self-sampling to Optimize Anal Lesion Outcomes · NA · recruiting
- NCT07296237 — Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer · recruiting
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
- NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
- NCT06670495 — HPV Genotype Attribution and Disease Burden of Anal Cancer in China · recruiting
Other Centre Francois Baclesse trials
Trials by the same sponsor.
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
- NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
- NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
- NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03506529 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
- Last refreshed: 11 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03506529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing